Panbela Schedules Conference Call on March 24, 2022, to Report 2021 Fourth Quarter Financial Results
March 08 2022 - 8:30AM
Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage
biopharmaceutical company developing disruptive therapeutics for
the treatment of patients with cancer, today announced that it will
host a conference call on March 24, 2022 at 4:30 PM Eastern Time to
discuss results for its fourth quarter ended December 31, 2021.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes
before the beginning of the call.
Date: March 24, 2022Time: 4:30 PM Eastern TimeToll Free:
888-506-0062; Access Code: 461101International: 973-528-0011;
Access Code: 461101
The call will also be available over the Internet and accessible
at: https://www.webcaster4.com/Webcast/Page/2556/44452
Conference Call Replay Information
Toll Free: 877-481-4010International: 919-882-2331Replay
Passcode: 44452
About SBP-101
SBP-101 is a proprietary polyamine analogue designed to induce
polyamine metabolic inhibition (PMI) by exploiting an observed high
affinity of the compound for pancreatic ductal adenocarcinoma and
other tumors. The molecule has shown signals of tumor growth
inhibition in clinical studies of US and Australian metastatic
pancreatic cancer patients, demonstrating a median overall survival
(OS) of 12.0 months which is not yet final, and an objective
response rate (ORR) of 48%, both exceeding what is seen typically
with the standard of care of gemcitabine + nab-paclitaxel
suggesting potential complementary activity with the existing
FDA-approved standard chemotherapy regimen. In data evaluated from
clinical studies to date, SBP-101 has not shown exacerbation of
bone marrow suppression and peripheral neuropathy, which can be
chemotherapy-related adverse events. Serious visual adverse events
have been evaluated and patients with a history of retinopathy or
at risk of retinal detachment will be excluded from future SBP-101
studies. The safety data and PMI profile observed in the current
Panbela sponsored clinical trial provides support for continued
evaluation of SBP-101 in a randomized clinical trial. For more
information, please
visit https://clinicaltrials.gov/ct2/show/NCT03412799 .
About Panbela
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing disruptive therapeutics for patients with urgent
unmet medical needs. The company’s initial product candidate,
SBP-101, is for the treatment of patients with metastatic
pancreatic ductal adenocarcinoma, the most common type of
pancreatic cancer. Panbela Therapeutics, Inc. is dedicated to
treating patients with pancreatic cancer, ovarian cancer, and
exploring SBP-101’s potential for efficacy in combination with
other agents in other cancer indications. Further information can
be found
at www.panbela.com. Panbela
Therapeutics, Inc. common stock is listed on The Nasdaq Stock
Market LLC under the symbol PBLA.
Cautionary Statement Regarding Forward-Looking
StatementsThis press release contains “forward-looking
statements,” including within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as: “design,” “expect,” “may,”
“plan,” “potential,” and “seek.” Examples of
forward-looking statements include statements we make
regarding timing of enrollment and conduct of the ASPIRE
trial, participating sites, and outcomes. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs,
expectations, and assumptions regarding the future of our business,
future plans and strategies, projections, anticipated events and
trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of our
control. Our actual results and financial condition may differ
materially and adversely from the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause our actual results
and financial condition to differ materially from those indicated
in the forward-looking statements include, among others, the
following: ( i ) our ability to obtain additional funding
to complete this randomized clinical trial;
(ii) completion and success of our Phase 1 clinical
trial; (iii) the impact of the current COVID-19 pandemic on
our ability to initiate clinical sites
and complete enrollment in this clinical
trial; (iv) our ability to demonstrate the safety and effectiveness
of our SBP-101 product candidate (v) our ability to obtain
regulatory approvals for our SBP-101 product candidate in the
United States, the European Union or other international markets;
(vi) the market acceptance and level of future sales of our SBP-101
product candidate; (vii) the cost and delays in product development
that may result from changes in regulatory oversight applicable to
our SBP-101 product candidate; (viii) the rate of progress in
establishing reimbursement arrangements with third-party payors;
(ix) the effect of competing technological and market developments;
(x) the costs involved in filing and prosecuting patent
applications and enforcing or defending patent claims; and (xi)
such other factors as discussed in Part I, Item 1A under the
caption “Risk Factors” in our most recent Annual Report on Form
10-K, any additional risks presented in our Quarterly Reports on
Form 10-Q and our Current Reports on Form 8-K. Any forward-looking
statement made by us in this press release is based on information
currently available to us and speaks only as of the date on which
it is made. We undertake no obligation to publicly update any
forward-looking statement or reasons why actual results would
differ from those anticipated in any such forward-looking
statement, whether written or oral, whether as a result
of new information, future developments or otherwise.
Contact Information:
Investors:James CarbonaraHayden IR(646)
755-7412james@haydenir.com
Media:Tammy GroenePanbela Therapeutics, Inc.(952) 479-1196 ext.
170IR@panbela.com
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Sep 2023 to Sep 2024